Through the agreement, Celgene will have full access to Quanticel’s proprietary platform for the single-cell genomic analysis of human cancer, as well as Quanticel’s lead programs that target specific epigenetic modifiers to advance Celgene’s pipeline of innovative cancer therapies.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”